Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.

King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, Katz A.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):939-45. doi: 10.1016/j.ijrobp.2013.08.019. Epub 2013 Oct 9.

2.

Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.

Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Dawson NA, Taylor KL, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2013 Mar 13;8:58. doi: 10.1186/1748-717X-8-58.

3.

Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.

King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1043-8. doi: 10.1016/j.ijrobp.2008.05.059. Epub 2008 Aug 26.

PMID:
18755555
4.

Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.

Bhattasali O, Chen LN, Woo J, Park JW, Kim JS, Moures R, Yung T, Lei S, Collins BT, Kowalczyk K, Suy S, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2014 Feb 11;9:52. doi: 10.1186/1748-717X-9-52.

5.

Potency preservation following stereotactic body radiation therapy for prostate cancer.

Obayomi-Davies O, Chen LN, Bhagat A, Wright HC, Uhm S, Kim JS, Yung TM, Lei S, Batipps GP, Pahira J, McGeagh KG, Collins BT, Kowalczyk K, Bandi G, Kumar D, Suy S, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2013 Nov 1;8:256. doi: 10.1186/1748-717X-8-256.

6.

Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.

King CR, Brooks JD, Gill H, Presti JC Jr.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82. doi: 10.1016/j.ijrobp.2010.11.054. Epub 2011 Feb 6.

PMID:
21300474
7.

Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial.

Wiegner EA, King CR.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):442-8. doi: 10.1016/j.ijrobp.2009.07.1748. Epub 2010 Feb 4.

PMID:
20137864
8.

Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison.

Pinkawa M, Piroth MD, Holy R, Fischedick K, Klotz J, Székely-Orbán D, Eble MJ.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):23-8. doi: 10.1016/j.ijrobp.2010.05.054. Epub 2010 Sep 9.

PMID:
20832182
9.

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).

Janowski E, Chen LN, Kim JS, Lei S, Suy S, Collins B, Lynch J, Dritschilo A, Collins S.

Radiat Oncol. 2014 Nov 15;9:241. doi: 10.1186/s13014-014-0241-3.

10.

Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.

Katz A, Ferrer M, Suárez JF; Multicentric Spanish Group of Clinically Localized Prostate Cancer.

Radiat Oncol. 2012 Nov 20;7:194. doi: 10.1186/1748-717X-7-194.

11.

Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer.

Gomez CL, Xu X, Qi XS, Wang PC, Kupelian P, Steinberg M, King CR.

Pract Radiat Oncol. 2015 Jul-Aug;5(4):257-62. doi: 10.1016/j.prro.2015.01.006. Epub 2015 Mar 3.

PMID:
25749214
12.

Stereotactic body radiotherapy for organ-confined prostate cancer.

Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M.

BMC Urol. 2010 Feb 1;10:1. doi: 10.1186/1471-2490-10-1.

13.
14.

Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.

Dess RT, Jackson WC, Suy S, Soni PD, Lee JY, Abugharib AE, Zumsteg ZS, Feng FY, Hamstra DA, Collins SP, Spratt DE.

Cancer. 2017 May 1;123(9):1635-1642. doi: 10.1002/cncr.30519. Epub 2016 Dec 21.

PMID:
28001303
15.

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.

Rucinska M, Kieszkowska-Grudny A, Nawrocki S.

Strahlenther Onkol. 2016 Jul;192(7):449-57. doi: 10.1007/s00066-016-0971-2. Epub 2016 May 25.

16.

Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.

Sood S, Ju AW, Wang H, Lei S, Uhm S, Zhang G, Suy S, Carroll J, Lynch J, Dritschilo A, Collins SP.

Radiat Oncol. 2013 Aug 9;8:197. doi: 10.1186/1748-717X-8-197.

17.

Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.

Elias E, Helou J, Zhang L, Cheung P, Deabreu A, D'Alimonte L, Sethukavalan P, Mamedov A, Cardoso M, Loblaw A.

Radiother Oncol. 2014 Jul;112(1):83-8. doi: 10.1016/j.radonc.2014.06.009. Epub 2014 Jul 5.

PMID:
25005578
18.

Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients.

Jereczek-Fossa BA, Santoro L, Zerini D, Fodor C, Vischioni B, Dispinzieri M, Bossi-Zanetti I, Gherardi F, Bonora M, Caputo M, Vavassori A, Cambria R, Garibaldi C, Cattani F, Matei DV, Musi G, De Cobelli O, Orecchia R.

J Urol. 2013 Jun;189(6):2099-103. doi: 10.1016/j.juro.2013.01.005. Epub 2013 Jan 9.

PMID:
23313200
19.

Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.

Chen LN, Suy S, Wang H, Bhagat A, Woo JA, Moures RA, Kim JS, Yung TM, Lei S, Collins BT, Kowalczyk K, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2014 Jun 26;9:148. doi: 10.1186/1748-717X-9-148.

20.

Proctitis following stereotactic body radiation therapy for prostate cancer.

Joh DY, Chen LN, Porter G, Bhagat A, Sood S, Kim JS, Moures R, Yung T, Lei S, Collins BT, Ju AW, Suy S, Carroll J, Lynch JH, Dritschilo A, Collins SP.

Radiat Oncol. 2014 Dec 12;9:277. doi: 10.1186/s13014-014-0277-4.

Supplemental Content

Support Center